First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate

In patients with pulmonary sarcoidosis, initial treatment with methotrexate was noninferior to that with prednisone with regard to the change from baseline to week 24 in the percentage of the predicted FVC. Differences in the side-effect profile between methotrexate and prednisone may inform shared decision making by providers and patients about the appropriate treatment approach. (Funded by the Dutch Lung Foundation; PREDMETH ClinicalTrials.gov number, NCT04314193.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-05-18
DOI
https://doi.org/10.1056/nejmoa2501443
Citations
37
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
43.08

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate

Pascal Wielders, Vivienne Kahlmann, Rémy L.M. Mostard, H.N.A.J. van Rijswijk et al.
37 citations
New England Journal of Medicine
Sarcoidosis and Beryllium Toxicity Research
43.08
article

First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate

Pascal Wielders, Vivienne Kahlmann, Rémy L.M. Mostard, H.N.A.J. van Rijswijk, Hubertus F.J.M. Koopman, E.R. Marges, Brigitte A.H.A. Bogaarts, Marcel Veltkamp, Peter Iwan Bonta, M. Overgaauw, Marlies Wijsenbeek, Daan W. Loth, Stefan Walen, H. Krämer, Jan C. Grutters, L. Moonen, Catharina C. Moor, Jan van der Maten, René Kerstens, Montse Janssen Bonás, M. Wagenaar, Maria J. Overbeek, Esther J. Nossent
article en
37 citations

Abstract

In patients with pulmonary sarcoidosis, initial treatment with methotrexate was noninferior to that with prednisone with regard to the change from baseline to week 24 in the percentage of the predicted FVC. Differences in the side-effect profile between methotrexate and prednisone may inform shared decision making by providers and patients about the appropriate treatment approach. (Funded by the Dutch Lung Foundation; PREDMETH ClinicalTrials.gov number, NCT04314193.).

New England Journal of MedicineVol. 393(3)
Centraal Bureau voor de Statistiek (NL), Radboud University Nijmegen (NL), Leiden University Medical Center (NL), Catharina Ziekenhuis (NL), Medisch Spectrum Twente (NL), Erasmus MC (NL), Medisch Centrum Leeuwarden (NL), University Medical Center Utrecht (NL), Maastricht University (NL), Medisch Centrum Haaglanden (NL), St. Antonius Ziekenhuis (NL), OLVG (NL), Amphia Ziekenhuis (NL), Martini Ziekenhuis (NL), VieCuri Medisch Centrum (NL), Zuyderland Medisch Centrum (NL), ERN GUARD-Heart (NL), Isala (NL), Amsterdam University Medical Centers (NL), Rijnstate Hospital (NL), Jeroen Bosch Ziekenhuis (NL)
Lung Foundation Netherlands
Zero hunger
Openalex Percentile: Top 0%
Sarcoidosis and Beryllium Toxicity Research
43.08
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.